Actemra was approved by the US Food and Drug Administration (FDA) on March 18, 2020 to treat severe COVID-19 cases in hospitalized patients. The indication is for treatment with Remdesivir. Actemra is being marketed by Biogen, a company focused on the development of drugs that address unmet medical needs, and is based in Cambridge, Massachusetts. On March 12, 2020, Biogen announced that it had initiated a Phase III clinical trial of Actemra in combination with the antiviral drug remdesivir in
Actemra was approved by the US Food and Drug Administration (FDA) on March 18, 2020 to treat severe COVID-19 cases in hospitalized patients. The indication is for treatment with Remdesivir. Actemra is being marketed by Biogen, a company focused on the development of drugs that address unmet medical needs, and is based in Cambridge, Massachusetts.
On March 12, 2020, Biogen announced that it had initiated a Phase III clinical trial of Actemra in combination with the antiviral drug remdesivir in hospitalized patients with COVID-19. The trial will enroll patients in the United States and Europe to compare Actemra in combination with remdesivir versus remdesivir alone in reducing serious outcomes among patients hospitalized with COVID-19.
“In order to continue the search for a safe and effective COVID-19 vaccine, one of the most urgent needs in the world today is a safe and effective Actemra anti-COVID-19 treatment. While no approved vaccines exist, Actemra is the first FDA-approved monoclonal antibody for treating patients with severe COVID-19, providing an important option for hospitalized patients and their healthcare providers who continue to be on the frontlines treating COVID-19.